Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 90

Similar articles for PubMed (Select 14742814)

1.

Challenges to the FDA approval of mifepristone.

Calhoun BC, Harrison DJ.

Ann Pharmacother. 2004 Jan;38(1):163-8. No abstract available.

PMID:
14742814
2.

[Controversies regarding approval and use of mifepristone (RU 486)].

Strobel E.

Fortschr Med. 1993 Jun 10;111(16):271-3. German. No abstract available.

PMID:
8330824
3.

Abortion pill gets FDA approval.

SoRelle R.

Circulation. 2000 Oct 10;102(15):E9030-1. No abstract available.

4.

Regulatory considerations for determining postmarketing study commitments.

Meyer RJ.

Clin Pharmacol Ther. 2007 Aug;82(2):228-30. Epub 2007 May 30. Review.

PMID:
17538552
5.

FDA advisory panel voices persistent safety concerns.

Finkelstein JB.

J Natl Cancer Inst. 2006 Apr 5;98(7):439. No abstract available.

6.

Report hits FDA to revamp safety oversight.

Finkelstein JB.

J Natl Cancer Inst. 2006 Jul 5;98(13):884-5. No abstract available.

7.

US Senate passes FDA Revitalization Act.

Guthrie P.

CMAJ. 2007 Jul 3;177(1):23. No abstract available.

8.

RU-486 and implications for use among adolescents seeking an abortion.

Meier E.

Pediatr Nurs. 2000 Jan-Feb;26(1):93-4. No abstract available.

PMID:
12026325
9.

The FDA in 2006: reasons for optimism.

Chabner BA, Roberts TG.

Oncologist. 2007 Mar;12(3):247-9. No abstract available.

10.

The FDA and drug safety: a proposal for sweeping changes.

Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL.

Arch Intern Med. 2006 Oct 9;166(18):1938-42.

PMID:
17030825
11.

New warning for mifepristone and misoprostol.

[No authors listed]

Lancet. 2005 Jul 30-Aug 5;366(9483):344. No abstract available.

PMID:
16075477
12.

Blowing the whistle at the FDA.

Simons J.

Fortune. 2005 Jan 24;151(2):32. No abstract available.

PMID:
15693304
13.

FDA plans to continue cracking down on unapproved drugs.

Lavine G.

Am J Health Syst Pharm. 2008 Sep 1;65(17):1594. doi: 10.2146/news080072. No abstract available.

PMID:
18714097
15.

FDA attempting to overcome major roadblocks in monitoring drug safety.

Zielinski SL.

J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. No abstract available.

16.

Tuft's report backs FDA fast-track, but post-marketing concerns loom.

Vastag B.

Nat Biotechnol. 2006 May;24(5):478. No abstract available.

PMID:
16680113
17.

US lawmakers tackle safety reforms at the FDA.

Zwillich T.

Lancet. 2007 Jun 16;369(9578):1989-90. No abstract available.

PMID:
17577942
18.
19.

Update on medication abortion.

Beal MW.

J Midwifery Womens Health. 2007 Jan-Feb;52(1):23-30. Review.

PMID:
17207747
20.

FDA guidance document on monitoring delayed adverse events a good first start.

Williams DA.

Mol Ther. 2005 Dec;12(6):991-2. Epub 2005 Nov 3. No abstract available.

PMID:
16271514
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk